This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
EBioMedicine EBioMedicine is a peer-reviewed biomedical journal covering translational research that bridges laboratory science and clinical application. Founded to accelerate cross-disciplinary communication among researchers, clinicians, institutions, and funders, the journal situates work at the intersection of National Institutes of Health-funded basic science, Food and Drug Administration-regulated clinical trials, and implementation studies from major centers such as Johns Hopkins University, Mayo Clinic, and Massachusetts General Hospital. Its remit attracted submissions from investigators associated with organizations including Harvard University, Stanford University, University of Oxford, University of Cambridge, and companies like Pfizer, Roche, and Novartis.
The journal was launched amid a broader movement toward translational platforms in the 21st century, paralleling initiatives by Wellcome Trust, Howard Hughes Medical Institute, and the translational medicine agendas of national agencies such as National Health Service partners. Early editorial figures included editors and advisors drawn from institutions like Imperial College London, University of California, San Francisco, and Karolinska Institutet, linking laboratory programs at places such as the Salk Institute and the Broad Institute with clinical networks at Cleveland Clinic and Cedars-Sinai Medical Center. The title expanded its scope as precision medicine projects—exemplified by the Human Genome Project, the 100,000 Genomes Project, and the rise of CRISPR-based trials—gained prominence, adapting policies in response to initiatives from funders like the Wellcome Trust and regulatory changes by the European Medicines Agency.
The journal emphasizes translational studies across domains represented by major research programs such as Cancer Moonshot, All of Us Research Program, and vaccine development efforts exemplified by Operation Warp Speed collaborations. Topics commonly published include immuno-oncology studies connected to centers like Dana-Farber Cancer Institute and therapeutic developments aligned with companies such as Moderna and AstraZeneca, alongside diagnostics developed by teams at Centers for Disease Control and Prevention laboratories. The aims echo priorities articulated by stakeholders including Bill & Melinda Gates Foundation, Wellcome Trust, and national funders like the European Research Council and the National Science Foundation in promoting translational pipelines from benchwork at places like Cold Spring Harbor Laboratory to bedside studies at Vanderbilt University Medical Center.
Editorial governance drew on practices established by major publishers and journals associated with The Lancet, Nature Medicine, and New England Journal of Medicine. Editorial boards comprised academics and clinicians from institutions such as Yale University, Columbia University, Johns Hopkins University School of Medicine, and industry representatives from firms like GlaxoSmithKline and Johnson & Johnson. Peer review processes mirrored standards promoted by organizations including the Committee on Publication Ethics and the International Committee of Medical Journal Editors, employing external reviewers from research groups at ETH Zurich, University of Toronto, National University of Singapore, and specialist reviewers from disease-focused centers like St. Jude Children's Research Hospital and Fred Hutchinson Cancer Research Center.
The journal adopted an open access model in line with policies advocated by funders such as Wellcome Trust and mandates like those from the National Institutes of Health public access policy. Publication workflows incorporated submission systems used by publishers linked to titles like Nature, Cell Press, and BMJ, enabling integrations with preprint servers popularized by bioRxiv and medRxiv. Article processing charges and waiver schemes reflected funding landscapes influenced by agencies including the Gates Foundation and national research councils such as the Japan Society for the Promotion of Science. Archiving and indexing practices intersected with databases curated by PubMed Central, Scopus, and Web of Science.
The journal’s impact was evaluated through bibliometric metrics familiar from comparisons with Science Translational Medicine, Nature Communications, and PLOS Medicine. Institutional readership included investigators at MIT, Princeton University, and major hospitals like Mount Sinai Health System. Reviews and commentary about the journal appeared alongside discussions involving editors and authors from venues such as The BMJ and panels at conferences run by American Association for the Advancement of Science and American Society of Clinical Oncology. Citation patterns reflected influence across fields represented by projects like the Human Cell Atlas and consortia including the International Cancer Genome Consortium.
Notable publications included translational reports linked to landmark programs such as vaccine development collaborations involving Oxford University teams, antibody discovery studies comparable to efforts at Regeneron Pharmaceuticals, and biomarker studies connected to consortia like the Cancer Genome Atlas. Series and themed collections often featured guest editors from institutions including Scripps Research Institute, The Rockefeller University, and University of Pennsylvania, focusing on topics that intersected with policy initiatives by World Health Organization task forces and global health partnerships with UNICEF.
Like many biomedical journals, it faced occasional controversies involving methodological critiques similar to disputes seen in publications from Lancet and Science, and retractions paralleling cases managed by editorial offices at Proceedings of the National Academy of Sciences and Nature. Issues prompting corrections or withdrawals included statistical concerns raised by groups at University of Oxford and reproducibility debates associated with labs formerly linked to controversies at institutions such as Hwang Woo-suk-related inquiries (contextualized with rigorous editorial responses). Editorial adjudications invoked standards promoted by the Committee on Publication Ethics and involved institutional investigations at universities and hospitals.
Category:Biomedical journals